[
  {
    "ts": null,
    "headline": "OPKO Health Q4 Earnings Call Highlights",
    "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
    "url": "https://finnhub.io/api/news?id=de3bc70686768dfe5f9e5efa067f9c6598800e9e6e5498aafc68873d9e89375f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772172776,
      "headline": "OPKO Health Q4 Earnings Call Highlights",
      "id": 139244673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "OPKO Health (NASDAQ:OPK) executives said the company exited 2025 with “tremendous momentum,” citing efforts to reposition its diagnostics business for a return to profitability, advance its ModeX therapeutic pipeline, use non-dilutive partnership funding to support R&D, and strengthen the balanc",
      "url": "https://finnhub.io/api/news?id=de3bc70686768dfe5f9e5efa067f9c6598800e9e6e5498aafc68873d9e89375f"
    }
  }
]